Head-to-head · free
The Precision Peptide Company vs Sky
PNGAF vs SKY — return on capital, cash generation, margins and balance sheet side by side.
PNGAF
0 / 0
measures where PNGAF leads
SKY
0 / 0
measures where SKY leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | PNGAF | SKY · FY2026 |
|---|---|---|
| Revenue | — | $2.7B |
| Net income | — | $206.9M |
| Revenue growth (yearly, multi-year) | — | 4.8% |
| Free cash flow | — | $269.7M |
| Free cash flow margin | — | 10.1% |
| Net cash / (debt) | — | — |
| ROIC | — | 11.5% |
| Return on equity | — | 13.3% |
| Gross margin | — | 26.4% |
| Operating margin | — | 9.5% |
| Net debt / EBITDA | — | -1.74x |
Figures are as reported by each company; latest fiscal year shown.
Where Sky's cash went (FY2026)
- Capital spending
- $34.1M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free